|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.78 DKK | +1.13% |
|
+0.75% | -0.88% |
| 03:07pm | Lundbeck beats expectations (Update) | FW |
| 03:01pm | Lundbeck posts growth in revenue and adjusted EBITDA | FW |
Business description: H. Lundbeck A/S
Number of employees: 5,039
Sales by Activity: H. Lundbeck A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
Research, Development, Production and Sale of Pharmaceuticals | 1.63TCr | 1.82TCr | 1.99TCr | 2.2TCr | 2.46TCr |
Geographical breakdown of sales: H. Lundbeck A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
United States | 745.6Cr | 910.2Cr | 982.9Cr | 1.13TCr | 1.33TCr |
Europe | - | 425.2Cr | 462.8Cr | 514.6Cr | 581.9Cr |
International Operations | 415.5Cr | 520.3Cr | 499.1Cr | 521.9Cr | 485.8Cr |
Unallocated | 40Cr | -31Cr | 46Cr | 31Cr | 67Cr |
North America (Excl. US) | 79Cr | - | - | - | - |
Europe (Excl.Denmark) | 346.9Cr | - | - | - | - |
Denmark | 3Cr | - | - | - | - |
Executive Committee: H. Lundbeck A/S
| Manager | Title | Age | Since |
|---|---|---|---|
Charl van Zyl
CEO | Chief Executive Officer | 59 | 01/10/2023 |
Jörg Hornstein
DFI | Director of Finance/CFO | 49 | 01/09/2022 |
| Chief Operating Officer | 52 | - | |
Johan Luthman
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/03/2019 |
Jens Høyer
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: H. Lundbeck A/S
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 25/03/2015 | |
| Director/Board Member | 66 | 25/03/2015 | |
| Director/Board Member | 60 | 20/03/2018 | |
Dorothea Wenzel
CHM | Chairman | 57 | 26/03/2025 |
Santiago Arroyo
BRD | Director/Board Member | 66 | 23/03/2021 |
| Director/Board Member | 54 | 01/01/2022 | |
Hossein Armandi
BRD | Director/Board Member | 64 | 01/01/2022 |
Lasse Skibsbye
BRD | Director/Board Member | 43 | 01/01/2022 |
Jakob Riis
BRD | Director/Board Member | 60 | 01/01/2023 |
Lars Green
BRD | Director/Board Member | 59 | 26/03/2025 |
Company details: H. Lundbeck A/S
Pharmaceuticals Wholesale
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.13% | +0.75% | +41.66% | +16.69% | 637.36Cr | |
| -1.48% | -10.23% | +4.57% | +84.97% | 8.72TCr | |
| -0.63% | -7.39% | +23.13% | +115.11% | 4.27TCr | |
| +0.35% | -2.40% | -6.86% | +304.26% | 2.37TCr | |
| +0.51% | +0.24% | -13.77% | -18.46% | 862.8Cr | |
| +0.47% | +0.35% | -5.61% | -21.69% | 846.63Cr | |
| +0.16% | -1.07% | -0.86% | -30.73% | 734.64Cr | |
| +0.89% | +0.37% | -3.12% | +8.14% | 523.79Cr | |
| -0.20% | -2.51% | -2.89% | -12.56% | 369.85Cr | |
| +1.31% | -1.05% | +12.64% | +32.22% | 358.82Cr | |
| Average | +0.31% | -2.23% | +4.89% | +47.79% | 1.97TCr | |
| Weighted average by Cap. | -0.48% | -5.91% | +6.78% | +97.43% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HLUN B Stock
- Company H. Lundbeck A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition